Two Indian pharmaceutical manufacturers, Glenmark Pharmaceuticals and Torrent Pharmaceuticals, and a Bahamian drugmaker Coral Pharmaceutical receives warnings from the U.S. Food and Drug Administration. The drugmakers were sent warning letters on violating the GMP guidelines at their facilities.
The warning letter to the Glenmark Pharmaceutical addressed its failures on investigating out-of-specification (OOS) test results and` temperature discrepancies during product shipments from its Himanchal Pradesh facility. Torrent Pharmaceutical receives warning for not investigating OOS over the Losartan Potassium tablets, while the letter to Coral Pharmaceutical cites control issues related to a homeopathic drug at its Freeport City facility.